|
LFM-A13
A BTK inhibitor
Product Overview
Product Name: LFM-A13
Alternate Name/Synonyms: (2Z) -2-Cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide
Description: FM-A13 is a selective inhibitor of Bruton’s tyrosine kinase (BTK) – IC₅₀’s = 2.5 µM (recombinant BTK) and 17.2 µM (human BTK). It has also been shown to inhibit Polo-like kinase (PLK) (IC₅₀ = 61 µM for human PLK3). It displays no activity (concentrations up to 278 µM) at JAK1, JAK3, HCK, EGFRK and IRK2 or CDK1-3, CHK1, IKK, MAPK1, SAPK2a and ten tyrosine kinases.
Peptide Sequence: N/A
Appearance: White solid
Formulation: N/A
CAS Number: 244240-24-2
Molecular Formula: C11H8Br2N2O2
Molecular Weight: 360
Purity: ≥98% by TLC
Solubility:DMSO (~15 mg/ml) or EtOH (~15 mg/ml)
Storage Temp.: -20 ̊C
Shipping Conditions: gel pack
Handling: Protect from light and air
SMILES: CC(=C(C#N)C(=O)NC1=C(C=CC(=C1)Br)Br)O
InChi: InChI=1S/C11H8Br2N2O2/c1-6(16)8(5-14)11(17)15-10-4-7(12)2-3-9(10)13/h2-4,16H,1H3,(H,15,17)/b8-6-
InChi Key: SVTDVJQAJIFG-VURMDHGXSA-N
PubChem CID: 54676905
MDL Number: MFCD09878279
USAGE: For Research Use Only! Not For Use in Humans. |